Target intelligence / Profile preview

Cytochrome P450 3A4, 2C9, 2D6, and 2B6 (CYP3A4, CYP2C9, CYP2D6, CYP2B6)

Target
CYP3A4, CYP2C9, CYP2D6, CYP2B6
Molecular classification
Enzyme, Cytochrome P450 monooxygenase, Microsomal oxidase, Heme-containing enzyme
01

Overview

Cytochrome P450 3A4, 2C9, 2D6, and 2B6 are heme-containing enzymes encoded by their respective genes and predominantly located in the liver[1][2][5][8][10]. They oxidize a wide variety of exogenous substrates including pharmaceuticals and toxins, as well as some endogenous compounds. CYP3A4 and CYP2D6 in particular are responsible for the metabolism of the majority of prescription drugs, with CYP3A4 known for its broad substrate specificity and high potential for drug-drug interactions due to its ability to bind multiple compounds simultaneously[6][7]. Genetic variability in CYP2D6 and CYP2B6 explains significant differences in drug response and therapy outcomes between patients[5][8]. These enzymes represent major nodes for safety and efficacy concerns in drug development and precision medicine.

Other names
CYP3A4CYP2C9CYP2D6CYP2B6drug-metabolizing cytochromes P450
02

Mechanism of action

Substrate oxidation (drugs are metabolized, activated, or deactivated), competitive inhibition, enzyme induction or repression, allosteric/cooperative substrate binding.

03

Biological functions

Xenobiotic metabolismDrug metabolism and detoxificationBiosynthesis of cholesterol, steroids, and other lipids (limited involvement)Oxidation of small organic molecules
04

Disease associations

Adverse drug reactionsCancer, via activation of procarcinogens (especially CYP3A4)Interaction-related toxicity (drug-drug interactions)Variable drug response in infection and cardiovascular disease due to pharmacogenetic variation
05

Safety considerations

High risk of drug-drug interactions due to shared metabolism pathwaysAdverse reactions and toxicity from enzyme inhibitors/inducersGenetic polymorphisms leading to unpredictable drug responsesActivation of pro-carcinogens (especially with CYP3A4)Loss of efficacy or increased toxicity with poor or ultra-rapid metabolizer genotypes
06

Interacting drugs

Antidepressants

22 more in the full profile.

07

Biomarkers

Genetic polymorphisms in CYP2D6 and CYP2C9 (used for predicting drug metabolism rates and risk of adverse reactions)Enzyme activity measured for dose adjustment and patient selection

Beyond the preview

Go deeper on Cytochrome P450 3A4, 2C9, 2D6, and 2B6 (CYP3A4, CYP2C9, CYP2D6, CYP2B6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 3A4, 2C9, 2D6, and 2B6 (CYP3A4, CYP2C9, CYP2D6, CYP2B6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call